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We here report the influence of the cell cycle abrogator UCN-01 on RKO human co-
lon carcinoma cells differing in p53 status following exposure to two DNA damaging
agents, the topoisomerase inhibitors etoposide and camptothecin. Cells were treated
with the two drugs at the IC90 concentration for 24 h followed by post-incubation in
drug-freemedium.RKOcellsexpressingwild-type,functionalp53arrestedthecellcy-
cle progression in both the G1 and G2 phases of the cell cycle whereas the RKO/E6
cells, which lack functional p53, only arrested in the G2 phase. Growth-arrested cells
didnotresumeproliferationevenafterprolongedincubationindrug-freemedium(up
to 96 h). To evaluate the importance of the cell cycle arrest on cellular survival, a
non-toxic dose of UCN-01 (100 nM) was added to the growth-arrested cells. The addi-
tion of UCN-01 was accompanied by mitotic entry as revealed by the appearance of
condensed chromatin and the MPM-2 phosphoepitope, which is characteristic for mi-
totic cells. G2 exit and mitotic transit was accompanied by a rapid activation of
caspase-3 and apoptotic cell death. The influence of UCN-01 on the long-term
cytotoxic effects of the two drugs was also determined. Unexpectedly, abrogation of
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saline; MTT, Thiazolyl blue; TBS, Tris-buffered saline.the G2 arrest had no influence on the overall cytotoxicity of either drug. In contrast,
addition of UCN-01 to cisplatin-treated RKO and RKO/E6 cells greatly increased the
cytotoxic effects of the alkylating agent. These results strongly suggest that even pro-
longedcellcyclearrestintheG2phaseofthecellcycleisnotnecessarilycoupledtoef-
ficient DNA repair and enhanced cellular survival as generally believed.
Exposure to DNA damaging agents leads to
growth arrest in the G1 and G2 phases of the
cell cycle thereby preventing the cells from
replicating and separating the damaged DNA.
The growth arrest is due to activation of dif-
ferent cell cycle checkpoints (surveillance pro-
teins) which are activated by DNA damage or
aberrant DNA replication. It is generally be-
lieved that the cell cycle arrest provides the
cells with additional time to repair the poten-
tially lethal DNA lesions, thereby rendering
them more resistant to the cytotoxic effects of
DNA damaging agents [1]. To overcome the
cell cycle arrest induced by conventional
cytotoxic anticancer drugs, new checkpoint
abrogators, such as the staurosporine deriva-
tive UCN-01, have been developed. UCN-01 is
able to block at least part of the stress signal-
ing induced by DNA damaging agents,
thereby triggering premature entry of the
damaged cells into mitosis [2]. As expected,
abrogation of the G2 checkpoint is accompa-
nied by increased cytotoxicity of many
anticancer agents both in vitro and in vivo [3,
4]. UCN-01 is currently under clinical trials
bothasasingleagentandincombinationwith
other drugs as a cell cycle modulator [5].
The tumor suppressor protein p53 is a key
regulator of stress-induced pathways which
controlDNArepair,cellcycleprogressionand
celldeath.Inparticular,p53isrequiredforG1
but not for G2 arrest although functional p53
appears to strengthen the G2 arrest (for re-
cent review see [6]). p53 is a transcription fac-
tor which can activate numerous genes
throughbindingtospecificDNAsequences in
their promoter regions. The p53 protein is ei-
ther absent or mutated in the majority of hu-
mancancers,includingcoloncarcinomas.The
influence of p53 on the cytotoxic effect of
anticancer agents remains controversial [7,
8]. The use of genetic models where p53 func-
tion has been disrupted either by expression
of the papillomavirus E6 protein [9–11] or
where the p53 gene has been disrupted by ho-
mologous recombination [12] shows conflict-
ing results since cells with non-functional p53
maybecomemoresensitive,moreresistantor
have unchanged sensitivity depending on the
agentandthecellularcontext.Ithasbeenpro-
posed that the influence of UCN-01 may also
be dependent on p53 status, since cells with
non-functional p53 rely totally on the G2 ar-
rest (which can be modulated by UCN-01),
whereas p53 proficient cells are also able to
arrest damaged cells in G1, which can not be
overcome by UCN-01 [5]. In this study, we de-
termined the influence of p53 function on the
G2 to M progression in RKO cells treated with
two DNA damaging agents, the
topoisomerase inhibitors camptothecin and
etoposide — in the absence or presence of
UCN-01.OurstudiesshowthatUCN-01isable
to provoke the G2 to M transition in both
etoposide- and camptothecin-treated cell irre-
spective of the p53 status. Unexpectedly,
accelerated mitotic entry was not accompa-
nied by enhanced cytotoxicity of the drug-
treated cells strongly suggesting that cell cy-
cle arrest and DNA repair are not necessarily
coupled during the G2 arrest as generally be-
lieved.
MATERIALS AND METHODS
Drugs,chemicalsandantibodies.UCN-01
was kindly provided by Dr. E. Sausville (Na-
tional Cancer Institute, Bethesda, MD,
U.S.A.). Etoposide (VP-16), camptothecin,
MTT (Thiazolyl blue), propidium iodide,
RNase A were purchased from Sigma (St.
Louis, MO, U.S.A.), caspase-3 activity kit and
purified caspase-3 were from BioMol (Ham-
110 P. Bozko and others 2002burg, Germany). Media, antibiotics and se-
rum were from Gibco (Paisley, U.K.).
Monoclonal anti-MPM-2 antibodies were from
Dako (Carpinteria, CA, U.S.A.), monoclonal
anti-cdc-2, polyclonal rabbit anti-p21, poly-
clonal rabbit anti-p53, polyclonal goat anti-
actin were from Santa Cruz (Santa Cruz, CA,
U.S.A.). Horseradish peroxidase-conjugated
anti-mouse, anti-rabbit and anti-goat IgG anti-
bodies were from Jackson ImmunoResearch
Labs (West Grove, PA, U.S.A.). All other re-
agents were from local provider.
Cells. RKO/neo and RKO/E6 transfected
cells were kindly provided by Dr. Joseph
Bertino (Sloan-Kettering Institute, New York,
NY, U.S.A.). Cells were maintained in MEM
minimal essential medium supplemented
with 10% foetal bovine serum and antibiotics
(0.1 g/ml streptomycin, 100 U/ml penicil-
lin). The cells were grown in a monolayer cul-
ture at 37C in a humidified 5% CO2/95% air
atmosphere. In these conditions the doubling
time for both cell lines was 24 h. In some ex-
periments,wealsousedRKOcellstransfected
with the empty vectro (RKO/neo). These cells
behaved similarly to the parental RKO cells.
Cytotoxic activity. The cytotoxic activity of
the drugs studied was determined by the MTT
assay. Briefly, cells (1  104 per well) were al-
lowed to attach in 24-well plates overnight be-
fore a 24-h exposure to drugs. Following two
washes with warm growth medium, cells were
incubated for an additional 96 h. The IC90 is
defined as the inhibitory drug concentration
causing90%reductionofA540absorbancever-
sus that of control. In some experiments, 100
nM UCN-01 was added for 8 h following drug
treatment.
Flow cytometry. Distribution of cells
through the cell cycle was measured by flow
cytometry using an EPICS Profile II Flow
Cytometer (Coulter, Hialeah, FL, U.S.A.)
equipped with an argon laser to give 488 nm
light. The cells were fixed in 70% ethanol at
–20°C, rehydrated in phosphate-buffered sa-
line (PBS) and stained with PBS containing
propidium iodide (20 g/ml) and RNase A
(100 g/ml) for 30 min at room temperature.
The percentage of cells in each phase of the
cell cycle was calculated by MultiPlus soft-
ware (Phoenix Flow Systems, San Diego, CA,
U.S.A.).Biparametricflowcytometryanalysis
ofMPM-2anddeterminationofthepositionof
cells in the cell cycle was performed as de-
scribed [13].
Caspase-3 activity assay. Drug-treated or
control cells (1  106) were lysed in 50 l
lysing buffer (50 mM Hepes, pH 7.4, 0.1%
Chaps, 5 mM dithiothreitol, 0.1 mM EDTA)
for 5 min on ice, centrifuged at 20000  g for
10minat4Candsupernatantscollected.Pro-
tein concentration was determined by the
bicinchoninic acid (BCA) assay and super-
natants were examined for caspase-3 activity
using the caspase-3 kit (BioMol) according to
the manufacturer’s instructions. Fold in-
crease in protease activity was determined by
comparing drug-induced values and non-
treated controls. Calibration curves were gen-
erated using purified caspase-3 (BioMol) and
the activity was expressed in units/g protein
per h.
Western blotting. Cells were lysed in RIPA
buffer(150mMNaCl,1mMEDTA,1%NP-40,
0.5% sodium deoxycholate, 0.1% sodium dode-
cyl sulfate (SDS), 50 mM Tris/HCl, pH 8) con-
taining protease inhibitor cocktail (Roche,
Meylan, France) and phosphatase inhibitors
(50 mM sodium fluoride, 50 mM -glycero-
phosphate, 1 mM sodium orthovanadate) for
15 min on ice. Cell lysates were centrifuged at
20000gfor10minat4Candsupernatants
collected.Proteinconcentrationincelllysates
was determined by the BCA assay. Equal
amounts (50 g per lane) were loaded in
Laemmli buffer and separated by SDS/PAGE
electrophoresis in 12% acrylamide gels and
transferred onto PVDF membranes (Amer-
sham Pharmacia Biotech, Uppsala, Sweden).
After transfer, membranes were blocked in
5% non-fat milk in TBS buffer (10 mM
Tris/HCl, 150 mM NaCl, pH 8) and washed in
TBST buffer (TBS buffer containing 0.05%
Tween-20). Membranes were incubated with
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ing 0.5% bovine serum albumin at 1:100
(anti-p53,p21andcdc2)or1:1000(anti-actin)
for 1–3 h at room temperature. After three
washes in TBST, membranes were incubated
with secondary antibodies diluted at 1:40000
in TBST for 1 h at room temperature. Results
were revealed by the ECL kit (Amersham
Pharmacia Biotech). Equal protein loading
was verified by re-hybridization of the mem-
branes and re-probing with anti-actin antibod-
ies.
DNA fragmentation. DNA fragmentation
in cells undergoing apoptosis was assayed es-
sentially as described [14]. Following drug
treatment, cells (2  106 per sample) were
harvested by centrifugation, washed twice
with ice-cold PBS, and lysed in 80 l lysing
buffer (10 mM Tris/HCl, 10 mM EDTA, 10
mM NaCl, 0.5% SDS, pH 7.4, and 0.5 mg/ml
proteinase K) for3ha t5 0 C. Following lysis,
the salt concentration (NaCl) was raised to
1 M and samples were centrifuged (30 min,
500  g). Supernatants were collected, DNA
was precipitated with ethanol overnight at
–20C. The DNA pellet was dissolved in 20 l
10 mM Tris/HCl, 15 mM NaCl, 1 mM EDTA,
pH 7.4, RNA digested with RNase A for 0.5 h
at 50C (0.2 mg/ml final concentration) and
samples separated by electrophoresis in 1.8%
agarose gel with TBE as a running buffer
(89 mM Tris, 89 mM boric acid, 2 mM EDTA,
pH 8) for 16 h at 1 V/cm. DNA was visualized
by ethidium bromide staining (0.5 g/ml,
1 h), destained overnight in re-distilled water,
and photographed under UV illumination.
RESULTS
p53 function in RKO and RKO/E6 cells
The expression of p53 protein in RKO and
RKO/E6 carcinoma cells was determined by
Westernblotanalysis.Theresultsshownode-
tectable p53 expression in RKO/E6 cells
(Fig. 1A, lane 1) and very low levels of p53 in
untreated RKO cells (Fig. 1A, lane 2). In con-
trast, p53 protein levels are markedly en-
hanced in RKO cells after 24 h exposure to
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Figure 1. Panel A: Expression
of p53 in non treated RKO and
RKO/E6 cells or RKO cells
treatedwith5MVP-16,50nM
camptothecin (CPT) or 5 M
cisplatin (cis- Pt) for 24 h as de-
termined by Western blotting.
PanelB:Cdc2phosphorylation
in RKO and RKO/ E6 cells
treated with 5 M VP-16 or 50
nM camptothecin for 24 h and
post-incubated with or without
100 nM UCN-01, as determined
by Western blotting.VP-16, camptothecin or cisplatin (Fig. 1A,
lanes 3–5). We also determined the induction
of the cyclin dependent kinase inhibitor
p21cip1 which is transcriptionally regulated
by p53 [15]. The results show that exposure of
RKO cells to etoposide or camptothecin re-
sults in a more than 10-fold increase in p21
proteinlevelascomparedwith untreatedcon-
trols. In contrast, drug treatment had essen-
tially no influence on p21 protein level in
RKO/E6 cells (not shown). These results sug-
gest that p53 is functional in the parental
RKO cells but not in the RKO/E6 subline.
Influence of DNA topoisomerase inhibitors
on cell cycle progression in RKO and
RKO/E6 cells
Theinfluenceofetoposideandcamptothecin
on the cell cycle distribution was determined
by flow cytometry after 24 h exposure fol-
lowed by post-incubation in drug-free media.
The DNA histograms show that parental RKO
cells which express functional wild-type p53,
are arrested in both the G1 and G2 phase of
thecellcycle (Fig.2A)whereasRKO/E6cells,
which lack functional p53, accumulate in the
G2 phase of the cell cycle (Fig. 2B). Interest-
ingly, the cell cycle arrest is remarkably sta-
ble, since none of the treated cells resume
proliferation even after as long as 96 h post-
incubation in drug-free media (not shown).
Furthermore, it is worth noting that drug ex-
posure is accompanied by formation of poly-
ploid RKO cells as indicated by the presence
of cells with an 8N content. This is most obvi-
ous for etoposide-treated cells, and to a lesser
extent for camptothecin-treated cells
(Fig. 2A). In contrast, no polyploid cells were
observed for the RKO/E6 cells. To establish if
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Figure 2. DNA histograms from RKO (panel A) and RKO/E6 (panel B).
Cells treated with 5 M VP-16 or 50 nM camptothecin for 24 h and post-incubated with or without 100 nM UCN-01,
as determined by flow cytometry. Abbreviations as in Fig. 1.the cells were arrested in G2 or in M, Western
blot analysis was carried out for Cdc2 kinase,
the major mitotic kinase. The results show
that growth arrest is accompanied by the ap-
pearanceofanewbandwithlowerelectropho-
retic mobility in SDS/PAGE gels indicative of
the phosphorylated inactive form of the
kinasewhichistypicalforcellsinG2(Fig.1B).
To determine the cellular consequences of
prolonged G2 arrest, a non-toxic dose (100
nM) of the cell cycle modulator UCN-01 was
added to the growth-arrested cells for 8 h. The
addition of UCN-01 results in rapid G2 exit
and mitotic entry as revealed by the appear-
ance of condensed chromatin and the MPM-2
phosphoepitope, which is characteristic for
mitotic cells (not shown). G2 exit is accompa-
nied by gradual activation of Cdc2 kinase as
shownbytheconversionoftheslowmigrating
phosphorylated inactive form into the faster
migrating dephosphorylated active form of
the kinase which is characteristic of mitotic
cells (Fig. 1B). In the absence of UCN-01, no
activation of Cdc2 kinase was observed
throughout the 8 h postincubation period.
Induction of cell death
Incubationofdrug-treatedcellswithUCN-01
wasaccompaniedbytheappearanceofcellsin
G1andsub-G1(Fig.2).Thissuggestedthatthe
G2 to M transition may be accompanied by in-
duction of apoptotic cell death. We therefore
measured the activity of caspase-3, one of the
major execution caspases. No measurable
caspase-3 activity was observed in etoposide-
or camptothecin-treated cells post-incubated
in drug-free medium for up to 12 h (Fig. 3A).
In contrast, post-incubation in the presence of
UCN-01 is associated with a clear induction of
caspase-3 activity. Interestingly, although the
kinetics of caspase-3 activation is similar for
the two drugs, the overall caspase-3 activity is
about 10-fold higher in camptothecin-treated
cellsthaninetoposide-treatedcellssuggesting
differencesinthecelldeathpathwaysinduced
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Figure 3. Panel A: Activation of
caspase-3 in RKO (gray bars) and
RKO/E6 (black bars) cells treated
with 5 M VP-16 or 50 nM cam-
ptothecin for 24 h and post-in-
cubated with or without 100 nM
UCN-01 for the time indicated.
Panel B: Analysis of DNA frag-
mentation in RKO and RKO/E6
cells treated with 5 M VP-16 or
50 nM camptothecin for 24 h and
post-incubated with or without
100 nM UCN-01 for the time indi-
cated. M, 123 bp DNA ladder; C,
non-treated cells.by the two drugs. We also determined if in-
creased caspase-3 activity was accompanied
by other markers of cell death such as DNA
fragmentation.IncreasedDNAfragmentation
is observed for drug-treated cells post-in-
cubated with UCN-01, whereas no significant
DNA fragmentation is observed in drug-tre-
ated cells which were post-incubated in
drug-free medium for up to 12 h (Fig. 3B).
Influence of UCN-01 on the cytotoxicity of
camptothecin and etoposide
Next, we wished to establish if the UCN-01
mediated caspase activation was accompa-
niedbyincreasedlong-termcytotoxicity.Cells
were treated with either drug for 24 h,
post-incubated in the absence or presence of
non-toxic doses of UCN-01 for 8 h followed by
post-incubation in drug-free medium for an
additional 4 days. Unexpectedly, in spite of
the rapid induction of apoptotic cell death,
UCN-01 had no influence on long-term
cytotoxicity of either drug (Fig. 4). In con-
trast, postincubation with UCN-01 increased
the cytotoxicity of cisplatin, a classical
alkylating agent, 3-fold (not shown). There-
fore, although UCN-01 successfully was able
to overcome the G2 arrest for all three DNA
damaging agents, this was accompanied by in-
creased long-term cytotoxicity for only one of
them.
DISCUSSION
Inthepresentstudy,weinvestigatedtherole
of the tumor suppressor protein p53 in the G2
to M progression induced by a well known
checkpoint abrogator, a staurosporine deriva-
tiveUCN-01.Inparticular,wewereinterested
in long-term survival of G2-arrested cells by
sublethal doses of DNA topoisomerase inhibi-
tors in which G2 to M progression was in-
duced by UCN-01. We used human colon car-
cinoma RKO cells expressing functional p53
protein and its subline with disrupted p53
function by expression of the E6 protein. We
found that G2 to M transition induced by
UCN-01 occurred in both RKO cell lines inde-
pendently of their p53 status. Surprisingly,
thisfacilitatedG2exitwasnotassociatedwith
enhanced long-term cytotoxic effect of cam-
ptothecin or etoposide.
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Figure4.LossofviabilityofRKOandRKO/E6cellstreatedwithVP-16(A)andcamptothecin(B)for24h
and post-incubated with or without 100 nM UCN-01 for 8 h, as determined by the MTT assay after 96 h
post-incubation in drug-free medium.
Symbols correspond to: () RKO () RKO+UCN-01; () RKO/E6; () RKO/E6+UCN-01.The role of p53 in G2 arrest and in the G2 to
M transition in response to DNA damage has
been somewhat controversial (for a recent re-
view see [6]) and seems to be cell type depend-
ent. Activation of p53 in myeloblasts from
p53-null mice and in murine leukemia cells
shortenedG2arrestinducedbyionizingradia-
tion [16] and etoposide [13] and led to rapid
induction of cell death and enhanced cyto-
toxicity. These and other results suggest that
p53 may not only shorten G2 arrest but also
stimulate the induction of cell death by its
pro-apoptotic activity during the G2 to M tran-
sition. Consistent with this, it has been re-
portedthatabrogationofG2arrestinducedby
DNA alkylators such as mitomycin C and
cisplatin by the checkpoint abrogators caf-
feine, pentoxiphylline or UCN-01 leads to en-
hanced cytotoxic effect [17] and synergistic
antitumor activity in vivo [5]. However, for
other drugs such as mitotic spindle poisons
(taxol, paclitaxel, vincristine) combination
with UCN-01 did not result in synergy [18].
There are also conflicting data concerning
the role of p53 in the increased cytotoxic ef-
fectassociatedwithcombinationwithUCN-01
and DNA topoisomerase inhibitors. Several
reports point to an enhanced activity of drug
combination in cells with non-functional p53
[3, 19–21], whereas other show no influence
of p53 status on cell sensitivity ([22], this
study). Part of the confusion probably stems
from the different treatment schedules used
in those studies. In most of the cases, cells
were treated simultaneously with both the
DNA-damaging agent and UCN-01 [3, 19–22].
This treatment procedure leads to the situa-
tion where UCN-01 abrogates both the
S-phaseandG2checkpoints(see,e.g.[19–21])
and not the G2 checkpoint alone (this study).
As mentioned above, the mechanism of
UCN-01 action is well defined only for the G2
to M transition, and no detailed molecular
mechanism concerning its role in S-phase
checkpoint abrogation has been proposed.
This is particularly surprising considering nu-
merous reports where potentiation of drug
cytotoxicitybyUCN-01throughitsabrogation
oftheS-phasecheckpointhasbeenfound(see,
e.g. [19–21]).
The results of our study show that UCN-01
induces G2 to M transition in RKO cells
treatedwithallthreedrugs,i.e.camptothecin,
etoposide as well as our reference compound,
cisplatin, independent of p53 status. How-
ever, an increased cytotoxic activity of
drug-UCN-01 combination was only observed
for cisplatin. This result suggests that
potentiation of cytotoxicity by abrogation of
the G2 checkpoint may be drug-dependent.
This is in agreement with previous reports
where pentoxiphylline, another DNA-damage
checkpoint abrogator, failed to synergistically
enhance the cytotoxic effect of taxol toward
malignantgliomatumorcells[18].Otherstud-
ies have shown that UCN-01 combinations
with paclitaxel and vincristine as well as
topoisomerase II inhibitors, adriamycin and
etoposide, do not result in synergy [3]. This
apparent discrepancy between molecular
events, i.e. the abrogation of drug-induced G2
arrest by UCN-01 and the cytotoxic effect of
drug-UCN-01 combination suggests several
different possibilities. First, it is possible that
in contrast to DNA alkylators, DNA damage
induced in tumor cells at a lethal dose of
camptothecin and etoposide is, at least in
part, non-repairable by celullar defense mech-
anisms activated in G2. In this case, irrespec-
tive of whether the drug-induced G2 arrest is
sustained by a DNA-damage checkpoint mech-
anism or is alleviated by UCN-01, this situa-
tion inevitably leads to cell death. In line with
that, it has been demonstrated that
UV-inducedDNArepair,mainlynucleotideex-
cision repair, is greatly reduced in RKO/E6
cells and dominant-mutant p53 transgenic
RKO cells which also correlated with de-
creased clonogenic survival following
UV-irradiation of cells with non-functional
p53 [23]. Nucleotide excision repair is be-
lieved to be the main process by which DNA
adducts induced by DNA alkylators such as
cisplatin are removed from DNA, although
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base excision repair and homologous DNA re-
combination, are also involved in DNA repair
of such lesions [24]. Inhibition of DNA
topoisomerases leads to the accumulation of
single and double strand DNA breaks as well
asundercondensedandentangledchromatids
[25]. The majority of DNA breaks caused by
topoisomerase inhibitors, especially those as-
sociated with the block of replication forks,
are repaired by homologous recombination
and non-homologous end-joining which are
preferentially active in S/G2 and G1, respec-
tively [26, 27].
Another possibility is that both DNA
topoisomerase inhibitors studied have differ-
entmechanismsofaction,oneofwhichisacti-
vated during the S phase and the other oper-
atesonlyduringtheG2phase.Therelativeim-
portance of the two mechanisms would proba-
blydependonthedrugconcentrationandcon-
sequently on the level of DNA damage in-
duced by it. This possibility might be particu-
larlyapplicabletocamptothecinforwhichtwo
cytotoxic mechanisms of action have been
proposed, one of which is protectable by
aphidicolin, i.e. depends on the ongoing DNA
replication, and the other is not [28]. Finally,
it is possible that cell death pathways induced
by different drugs might differ and might de-
pend or not on p53 status [29].
Together, our study shows that UCN-01 in-
duces G2 to M progression in tumor cells ar-
rested in the G2 phase of the cell cycle by
sublethal doses of both camptothecin and
etoposide, and the reference compound
cisplatin, independently of p53 function. Un-
expectedly, accelerated mitotic entry was not
associated with enhanced long-term cytotoxic
effect on cells treated with topoisomerase in-
hibitors. It follows that the ability of UCN-01
to overcome DNA damage-induced G2 arrest
was independent of both p53 function and the
nature of the agent used to induce the DNA
damage. However, the influence of G2 abroga-
tion on the long-term cytotoxicity was
strongly agent-specific with no effect for both
topoisomerase inhibitors studied and greatly
enhanced cytotoxicity for cisplatin. These re-
sults strongly suggest that cell cycle arrest
andDNArepairarenotalwaystightlycoupled
during G2 arrest as generally believed.
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